ArticleCancer informatics2019
A Holistic Evaluation of Articles on PD-1 and PD-L1 Published Between 1975 and 2017: A Bibliometric Analysis.
Article in Cancer informatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ferroptosis synergistically sensitizes wee1 inhibitors: a bibliometric study.American journal of translational research · 2022Article
- Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study.Frontiers in pharmacology · 2021Article
- A Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990-2019.Antioxidants (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBibliometrics has been used for assessing and predicting trends in macro-health science and medical systems, especially in the field of cancer. Bibliometric and scientometric studies in the field of programmed cell death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) may guide further research in this field.
objectiveTo perform bibliometric analysis of articles on PD-1 and PD-L1 published in the academic literature during 1975 to 2017.
methodThe bibliometric analysis was performed using the Thomson Reuters Web of Science database.
resultsA total of 23 813 articles were retrieved, 73.52% of which were original articles. The United States was the leading country by total publication number (n = 10 897, 10.91%), followed by China (10.54%), and produced the most literature on PD-1/PD-L1 (164.65 articles). Among the institutions identified, Harvard University (USA) contributed the most articles on PD-1/PD-L1.
conclusionsAll authors and institutions in the top 10 contributor's lists were from the developed countries. Researchers from the developing and least-developed countries should be encouraged to perform novel studies on PD-1 and PD-L1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.